8.76
前日終値:
$9.16
開ける:
$9.17
24時間の取引高:
579.60K
Relative Volume:
1.49
時価総額:
$226.03M
収益:
$34.26M
当期純損益:
$-46.61M
株価収益率:
-1.6909
EPS:
-5.1806
ネットキャッシュフロー:
$-62.01M
1週間 パフォーマンス:
+7.09%
1か月 パフォーマンス:
+35.81%
6か月 パフォーマンス:
+123.47%
1年 パフォーマンス:
+81.37%
Precision Biosciences Inc Stock (DTIL) Company Profile
名前
Precision Biosciences Inc
セクター
電話
919-314-5512
住所
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
DTIL
Precision Biosciences Inc
|
8.76 | 226.03M | 34.26M | -46.61M | -62.01M | -5.1806 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 開始されました | Guggenheim | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-06-09 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 再開されました | BTIG Research | Buy |
| 2020-04-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-05 | 開始されました | Stifel | Buy |
| 2020-02-25 | 開始されました | William Blair | Outperform |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-22 | 開始されました | Barclays | Overweight |
| 2019-04-22 | 開始されました | Goldman | Buy |
| 2019-04-22 | 開始されました | JP Morgan | Overweight |
| 2019-04-22 | 開始されました | Jefferies | Buy |
すべてを表示
Precision Biosciences Inc (DTIL) 最新ニュース
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Grants Stock Units to New Employees Amid G - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 - BioSpace
Precision BioSciences (DTIL) Grants Inducement Awards to New Hir - GuruFocus
Precision BioSciences, Inc. Actuals & Estimates (TRADEGATE:PBS0) - TradingView
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? - Yahoo Finance
Enterprise value to revenue forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences Updates Investors with Latest Corporate Deck in July 2026 SEC 8-K Filing - Minichart
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B - TipRanks
Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timeline - Stock Titan
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Index - marketscreener.com
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Value Benchmark - marketscreener.com
Precision BioSciences added to Russell 2000 index - Investing.com
Precision BioSciences (DTIL) Joins Russell 2000 Index, Highlighting Growth Potential - GuruFocus
Precision BioSciences added to Russell 2000 index By Investing.com - Investing.com India
Index Expanding Market Visibility with Institutional Investors - Business Wire
Precision BioSciences Announces Inclusion in - Moomoo
Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell Small Cap Completeness Index - marketscreener.com
Precision BioSciences, Inc. Actuals & Estimates (DUS:PBS0) - TradingView
Price to sales forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences Inc (DTIL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to earnings forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences, Inc. Actuals & Estimates (NASDAQ:DTIL) - TradingView
Enterprise value to EBIT forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
Enterprise value to revenue forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
DTIL Forecast — Price Target — Prediction for 2027 - TradingView
Precision BioSciences earnings calendar and gene-editing focus, shares remain a small-cap biotech pl - AD HOC NEWS
Precision BioSciences Inc (DTIL) Institutional Confidence - TradingKey
Greenstone Biosciences And Intel Collaborate To Accelerate AI Driven Drug Discovery - BioPharma APAC
Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences (DTIL) AGM 2026 Summary - Quartr
Precision BioSciences Inc (DTIL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Precision BioSciences Inc (DTIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision BioSciences Inc (DTIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precision BioSciences Inc (DTIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precision BioSciences Inc (DTIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Precision BioSciences Extends Term Loan Maturity to 2029 - TipRanks
Precision BioSciences Extends Term Loan Maturity to 2029 in Amendment With Banc of California - TradingView
Precision BiosciencesEnters First Amendment To Loan And Security Agreement With Banc Of CaliforniaSEC Filing - TradingView
Precision BioSciences (NASDAQ: DTIL) amends loan and extends term to 2029 - Stock Titan
Precision BioSciences, Inc. Amends Loan and Security Agreement with Banc of California - marketscreener.com
Oppenheimer Maintains Precision BioSciences(DTIL.US) With Buy Rating, Raises Target Price to $20 - Moomoo
DTIL Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
These stocks are gapping in today's session - ChartMill
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlitetm in Landmark CREDENCE Trial - Lelezard
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity - Stock Titan
Director at Precision Bio (NASDAQ: DTIL) receives 20,979 restricted stock units - Stock Titan
Precision Biosciences (DTIL) director receives grant of 20,979 restricted stock units - Stock Titan
Precision Biosciences Inc (DTIL) 財務データ
収益
当期純利益
現金流量
EPS
Precision Biosciences Inc (DTIL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
大文字化:
|
ボリューム (24 時間):